Dihexa vs Cerebrolysin
Comparing synthetic peptide Dihexa with brain-derived peptide mixture Cerebrolysin for cognitive research.
Last updated: February 1, 2026
Dihexa
Cerebrolysin
Overview
Dihexa and Cerebrolysin represent fundamentally different approaches to potential cognitive enhancement. Dihexa is a synthetic, defined peptide targeting the HGF/c-Met pathway, while Cerebrolysin is a complex mixture of brain-derived peptides. Neither is FDA-approved; Cerebrolysin has some international approvals.
Key Facts
| Aspect | Dihexa | Cerebrolysin |
|---|---|---|
| Type | Synthetic peptide | Brain extract |
| Composition | Single defined molecule | Complex mixture |
| Source | Laboratory synthesis | Porcine brain |
| Mechanism | HGF/c-Met pathway | Neurotrophic (multiple) |
| FDA Status | Not approved | Not approved |
Fundamental Differences
| Characteristic | Dihexa | Cerebrolysin |
|---|---|---|
| Definition | Precisely defined | Complex, variable |
| Mechanism | Specific pathway | Multiple pathways |
| Manufacturing | Chemical synthesis | Biological extraction |
| Reproducibility | High | More variable |
| Characterization | Complete | Partial |
Mechanism Comparison
| Aspect | Dihexa | Cerebrolysin |
|---|---|---|
| Primary Target | HGF/c-Met | Multiple (BDNF-like) |
| Pathway | Specific | Broad |
| Proposed Effect | Synaptogenesis | Neuroprotection |
| Mechanistic Clarity | Higher | Lower |
How They Work
Dihexa:
- Angiotensin IV analog
- Potentiates HGF/c-Met signaling
- Claimed to promote synapse formation
- Very specific mechanism
Cerebrolysin:
- Contains various brain-derived peptides
- BDNF-like activity documented
- Multiple neurotrophic factors
- Broad, undefined mechanism
Evidence Comparison
| Aspect | Dihexa | Cerebrolysin |
|---|---|---|
| Human Trials | None | Multiple |
| Animal Studies | Limited (one group) | Multiple groups |
| Western Publications | Very few | Many |
| Clinical Experience | None | Decades |
Evidence Quality Assessment
Dihexa:
- No human data
- Single research group
- No independent replication
- Extraordinary claims unverified
Cerebrolysin:
- Human trials exist
- Cochrane reviews available
- Mixed but real clinical data
- Used clinically in some regions
Safety Profile
Dihexa Concerns
| Concern | Basis |
|---|---|
| HGF/c-Met and cancer | Pathway promotes tumor growth |
| No human data | Safety completely unknown |
| Potency claims | Concerning if true |
| Quality | Gray market only |
Cerebrolysin Profile
| Aspect | Information |
|---|---|
| Clinical use | Decades of experience |
| Side effects | Documented (injection site, etc.) |
| Serious events | Rare in trials |
| Prion concern | Theoretical (manufacturing controlled) |
Regulatory Status
| Aspect | Dihexa | Cerebrolysin |
|---|---|---|
| FDA | Not approved | Not approved |
| EU | Not approved | Some countries |
| Russia | Not approved | Approved |
| China | Not approved | Approved |
| Development | Abandoned | Limited Western interest |
Administration
| Aspect | Dihexa | Cerebrolysin |
|---|---|---|
| Route | Oral (claimed), injection | IV or IM |
| Course | Unknown | 10-30 day courses |
| Clinical Protocol | None | Established |
Manufacturing and Quality
| Factor | Dihexa | Cerebrolysin |
|---|---|---|
| Manufacturing | Unknown sources | EU GMP (EVER Pharma) |
| Quality Control | None | Pharmaceutical |
| Batch Consistency | Unknown | Controlled |
| Purity | Unknown | Documented |
Practical Comparison
| Factor | Dihexa | Cerebrolysin |
|---|---|---|
| Evidence for use | None | Weak but exists |
| Safety data | None | Substantial |
| Quality assurance | None | Available |
| Clinical experience | None | Decades |
| Cancer pathway concern | Yes | No |
Risk Assessment
| Risk Factor | Dihexa | Cerebrolysin |
|---|---|---|
| Unknown safety | Very high | Lower |
| Mechanism risk | High (oncogenic) | Low |
| Quality risk | Very high | Low (pharma source) |
| Overall risk level | Very high | Moderate |
Key Differences
| Factor | Dihexa | Cerebrolysin |
|---|---|---|
| Compound type | Defined synthetic | Complex extract |
| Evidence Level | Very low | Moderate |
| Human data | None | Available |
| Safety profile | Unknown | Documented |
| Cancer concern | Yes (HGF/c-Met) | No |
| Quality sources | None | Pharmaceutical |
| Clinical use | Never | Years of use |
Summary
- Dihexa is a synthetic peptide with interesting mechanism but no human data and significant safety concerns (oncogenic pathway)
- Cerebrolysin is a brain-derived mixture with decades of clinical use and documented (though limited) evidence
- Dihexa has no safety profile; Cerebrolysin has extensive clinical experience
- Dihexa’s HGF/c-Met mechanism raises cancer promotion concerns
- Cerebrolysin has pharmaceutical-grade availability; Dihexa does not
- Neither is FDA-approved, but Cerebrolysin has international approvals
- From a risk perspective, Cerebrolysin has known limitations; Dihexa has unknown dangers
This comparison is for educational purposes only. Neither compound is FDA-approved. Dihexa has no human safety data and works through a pathway involved in cancer. Cerebrolysin has clinical experience but insufficient Western evidence. Consult a healthcare provider for medical decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.